BVT Aktienanleihe EVT 28.06.2024/ DE000VM11FX4 /
6/10/2024 8:04:50 PM | Chg.-0.730 | Bid9:09:43 PM | Ask9:09:43 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
40.030EUR | -1.79% | 40.080 Bid Size: 50,000 |
42.190 Ask Size: 10,000 |
EVOTEC SE INH O.N. | 22.00 EUR | 6/28/2024 | Call |
GlobeNewswire
12/11/2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune c...
GlobeNewswire
11/7/2023
Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline
GlobeNewswire
2/15/2018
EVOTEC AG AND MARS INNOVATION ANNOUNCE FIRST FUNDED PROJECT UNDER LAB150 BRIDGE
GlobeNewswire
1/8/2018
APEIRON and Evotec Achieve First Milestone in Immuno-oncology Alliance with Sanofi
GlobeNewswire
11/29/2011
Directors' dealings:Evotec AG:Director's Dealings announcement according to §15a WpHG (the German Se...
GlobeNewswire
10/27/2011
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi
GlobeNewswire
9/9/2011
Directors' dealings:Evotec AG:Director's Dealings announcement according to §15a WpHG (the German Se...
GlobeNewswire
9/5/2011
Evotec and Roche agree to develop compound that could slow the progression of Alzheimer's disease
GlobeNewswire
9/5/2011
Evotec AG:Ad hoc:Evotec and Roche agree to develop compound that could slow the progression of Alzhe...
GlobeNewswire
8/18/2011
Evotec Receives Pre-clinical Milestone Payment as Part of its Discovery Alliance with Boehringer In...
GlobeNewswire
8/11/2011
Evotec reports 34% revenue and profitable earnings growth; revenue guidance raised
GlobeNewswire
8/11/2011
Evotec partners P2X7 antagonist programme, EVT 401, to a top tier global animal health company